Welcome to our dedicated page for Addex Therapeutics news (Ticker: ADXN), a resource for investors and traders seeking the latest updates and insights on Addex Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Addex Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Addex Therapeutics's position in the market.
Enamine Ltd. has extended its collaboration with Addex Therapeutics Ltd (ADXN), enhancing its drug discovery services in CNS small molecules. Enamine will utilize its extensive resources and expertise in medicinal chemistry and pharmacology to support Addex's research programs under a Full Time Equivalent (FTE) model. Enamine's innovation and large collection of over 225,000 building blocks are expected to positively impact Addex's lead finding activities. This partnership builds upon years of successful collaboration and will continue to foster advancements in drug discovery.
FAQ
What is the current stock price of Addex Therapeutics (ADXN)?
What is the market cap of Addex Therapeutics (ADXN)?
